All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Approves Linvoseltamab for Relapsed/Refractory Multiple Myeloma

July 2nd 2025

The FDA has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for use in patients with relapsed/refractory multiple myeloma.

Denosumab Biosimilar Earns European Approval in Advanced Malignancies Involving the Bone and Giant Cell Tumors of the Bone

July 2nd 2025

Denbrayce was approved in Europe for the treatment of skeletal-related events in advanced malignancies involving the bone and giant cell tumor of the bone.

CHMP Provides Positive Opinion for MRD Negativity as an End Point for Regulatory Myeloma Clinical Trials

July 2nd 2025

The EMA’s CHMP has issued a positive opinion for the use of MRD-negative CR as an end point for regulatory clinical trials for patients with myeloma.

Low KIM-1 Levels Are Associated With Improved Clinical Outcomes in Advanced RCC

July 2nd 2025

A research fellow from Dana-Farber Cancer Institute shares post hoc findings from the phase 3 JAVELIN Renal 101 trial.

Domvanalimab-Based Combo Aims to Leverage Anti-TIGIT Mechanism in Upper GI Cancers

July 2nd 2025

Sam Klempner, MD, discusses the ongoing evaluation of domvanalimab plus zimberelimab and chemotherapy in upper GI cancers.

Clinical "Gray Areas" Persist Amid Evolving Multiple Myeloma Treatment Strategies

July 2nd 2025

Ajai Chari, MD, expands on areas of uncertainty in multiple myeloma after his presentation at the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

OncLive’s FDA Approval Report: The Regulatory Rundown for June 2025

July 1st 2025

Here is your guide to all therapeutic options that were cleared by the FDA in June 2025 spanning tumor types.

Perioperative IMNN-001 Utilizes Novel Delivery Route in Advanced Ovarian Cancer

July 1st 2025

Premal Thaker, MD, discusses findings for IMNN-001 plus perioperative chemotherapy in up-front, advanced ovarian cancer.

Revisit Every OncLive On Air Episode From June 2025

July 1st 2025

Read a recap of the episodes of OncLive On Air that debuted in June 2025.

AI Tool Set to Transform Characterization and Treatment of Cancers

July 1st 2025

A team of researchers at Yale developed and tested a new AI tool to help better characterize the diversity of individual tumor cells.

Early Data Show 3-Year Survival Benefit, Potential Temferon-Mediated Disease Control in Glioblastoma Multiforme

July 1st 2025

Long-term survival signals with Temferon in 2 patients with newly diagnosed glioblastoma multiforme suggest potential mediation of disease progression.

Zanidatamab Nets European Approval in Pretreated HER2+ Biliary Tract Cancer

July 1st 2025

Zanidatamab has become the first HER2-targeted agent to gain conditional approval for HER2-positive biliary tract cancer in the European Union.

Expert Investigators Highlight Cross-Cancer Updates for Fellows From the 2025 AACR Annual Meeting

July 1st 2025

Experts in the fields of lung, head and neck, HER2+ breast, and hematologic cancers discuss notable updates for fellows from the 2025 AACR Annual Meeting.

First-Line Bemarituzumab Plus Chemo Hits OS End Point in FGFR2b+ Advanced Gastric Cancer

July 1st 2025

First-line bemarituzumab plus chemotherapy improved overall survival in advanced gastric/GEJ cancer with FGFR2b overexpression.

Bocodepsin/Binimetinib Is Tolerable, Shows Combinatorial Activity in NRAS-Mutant Metastatic Melanoma

July 1st 2025

Phase 2 findings from NAUTILUS supported the potential combinatorial activity of binimetinib plus bocodepsin in NRAS-mutant melanoma.

Approaches to Risk Stratification, Timing of Treatment Initiation Pose Challenges in Smoldering Myeloma

June 30th 2025

Ajai Chari, MD, highlighted key areas of debate in smoldering myeloma from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference.

Zelenectide Pevedotin Plus Pembrolizumab Is Safe and Active in Treatment-Naive, Cisplatin-Ineligible Advanced Urothelial Cancer

June 30th 2025

The combination of zelenectide pevedotin and pembrolizumab was safe and produced antitumor activity in cisplatin-ineligible urothelial cancer.

Study of Combined TIGIT/PD-1 Blockade Signals Potential Shift in Gastric Cancer Management

June 30th 2025

Kohei Shitara, MD, discusses the investigation of domvanalimab plus zimberelimab and chemotherapy in patients with gastric/GEJ/esophageal cancers.

Dr Renier Brentjens Recognized by Two Prominent Cancer Research Organizations

June 30th 2025

Renier Brentjens, MD, PhD, invited to address Damon Runyon Foundation, New York Academy of Sciences

Gedatolisib Displays Early Efficacy in mCRPC and Pretreated HER2+ Breast Cancer

June 30th 2025

Gedatolisib generated clinical activity in metastatic castration-resistant prostate cancer and HER2-positive breast cancer.